Minrad International, Inc. company, through its Minrad Inc. subsidiary, develops real-time image guidance products used in anesthesiology, orthopedics, neurosurgery, and interventional radiology. The company's technologies, including its SabreSource system, improve accuracy in surgical procedures and reduce radiation exposure. Minrad also makes handheld surgical instruments and generic inhalation anesthetics used in human and veterinary surgeries. In addition, the company is developing other anesthetic drugs that relieve patients' pain during surgery without the loss of consciousness. Minrad belongs to Indian pharma firm Piramal Healthcare.

Avacta will take a closer look and get back with you. The biophysics company makes its money from the exact science of detecting molecules. Its Avacta Analysis arm provides analytical and research services to the pharmaceutical, healthcare, and personal care industries. It also offers expert witness services to assist in pharmaceutical patent disputes and suspected counterfeiting cases. The company's technology arm has developed a product to help drug developers analyze and predict the potential usefulness of biological drug compounds. The company also owns veterinary laboratory services provider YorkTest Veterinary Services, and diagnostic test maker Curidium Medica.

Regeneron Pharmaceuticals was founded in 1988 and is based in Tarrytown, New York. Regeneron Pharmaceuticals, Inc., an integrated biopharmaceutical company, discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions in the United States. The company's commercial product includes ARCALYST (rilonacept) injection for subcutaneous use for the treatment of cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and children. Its products under Phase III clinical trials include Aflibercept for the treatment of oncology; VEGF Trap-Eye in wet AMD in patients for eye diseases; and ARCALYST versus placebo for the prevention of gout flares in patients initiating urate-lowering drug therapy. The company's products under clinical trials include REGN88, an antibody to the Interleukin-6 receptor (IL-6R) that is being evaluated in patients with rheumatoid arthritis; REGN421, an antibody to delta-like ligand-4 that is being developed for oncology; and REGN475, an antibody to nerve growth factor, which is being developed for the treatment of pain. Regeneron Pharmaceuticals also conducts other preclinical research programs in the areas of oncology and angiogenesis, ophthalmology, metabolic and related diseases, muscle diseases and disorders, inflammation and immune diseases, bone and cartilage, pain, and cardiovascular diseases. The company has strategic collaboration agreements with sanofi-aventis Group to discover, develop, and commercialize fully human monoclonal antibodies; and Bayer HealthCare LLC for the development of the VEGF-Trap-Eye.

ZARS Pharma, Inc. operates as a specialty pharmaceutical company that focuses on developing and commercializing topically administered drugs using its proprietary drug delivery technologies, primarily in the area of pain management. It is developing a portfolio of proprietary products and product candidates based on its Controlled Heat-Assisted Drug Delivery and phase-changing cream technologies. The company’s products include Pliaglis, a topical anesthetic cream for dermal anesthesia prior to painful cosmetic procedures, such as laser surgery and dermal filler injections; and Synera, a topical patch for providing dermal analgesia for potentially painful superficial procedures, such as venous access procedures involving needles and immunization injections of children. Its products also comprise ThermoProfen, which is entering into Phase 3 clinical trials for the treatment of mild to moderate chronic pain associated with osteoarthritis of the knee; and Ketoprofen DuraPeel, a Phase 1 clinical trial product for the treatment of acute musculoskeletal pain resulting from soft tissue injuries, such as muscle strains, ankle sprains, and sports injuries. In addition, the company is developing the Alprazolam Patch, which is in Phase 1 clinical trial, for the treatment of panic disorder. The company was formerly known as ZARS, Inc. and changed its name to ZARS Pharma, Inc. in July, 2007. The company was founded in 1996 and is based in Salt Lake City, Utah.

Green Foods Corporation company manufactures and sells nutritional products made from green barley grass and other natural ingredients. Of its lead products, its Green Magma provides healthy doses of vitamins, minerals, and antioxidants to promote overall wellness. Carrot Essence is beta-carotene and vitamin C supplement, and Magma Slim is a weight loss formula. Green Foods also makes products for pets, Barley Cat and Barley Dog. Dr. Yoshihide Hagiwara founded Green Foods Corporation, which sells its products throughout the US online and through brokers, in 1980.

Senesco Technologies Inc. company was founded in 1964 and is headquartered in New Brunswick, New Jersey. Senesco Technologies, Inc. (Senesco) is a development-stage biotechnology company. The Company along with its wholly owned subsidiary, Senesco, Inc., is engaged in utilizing its eucaryotic translation initiation Factor 5A, or Factor 5A, and deoxyhypusine synthase (DHS), and related technologies for inhibition in human health applications to develop approaches to treat inflammatory diseases and cancer. In agricultural applications the Company is developing and licensing Factor 5A, DHS and Lipase to enhance the quality and productivity of fruits, flowers, and vegetables and agronomic crops through the control of cell death, referred to herein as senescence, and growth in plants.

Chelsea Therapeutics International, Ltd. was founded in 2002 and is headquartered in Charlotte, North Carolina. Chelsea Therapeutics International, Ltd., a development stage pharmaceutical company, focuses on the acquisition, development, and commercialization of pharmaceutical products for the treatment of various human diseases. It offers droxidopa, an orally active synthetic precursor of norepinephrine, which is in two double-blind pivotal Phase III trials for the treatment of symptomatic neurogenic orthostatic hypotension, freezing gait in Parkinson's disease, and intradialytic hypotension; for the treatment of intradialytic hypotension for which it has completed a double-blind placebo controlled Phase II study; and for the treatment of fibromyalgia that is in a Phase II trial.Chelsea Therapeutics company also offers a portfolio of molecules for the treatment of various autoimmune/inflammatory diseases, such as a portfolio of metabolically inert antifolate molecules, including CH-1504 for the treatment of rheumatoid arthritis that is in a Phase II head-to-head clinical trial; and CH-4051, which is in the Phase I study designed to determine the maximum tolerated dose based on results of single-ascending and multiple-ascending dose evaluations. In addition, it develops antifolate program, a second platform consisting of a portfolio of dihydroorotate dehydrogenase(DHODH), inhibiting compounds known as the I-3D portfolio, a group of orally active compounds that inhibit the enzyme DHODH for the treatment of immune-mediated inflammatory disorders, including transplant rejection, autoimmune diseases, psoriasis, and systemic lupus erythematosus.

Abbott Nutrition company manufactures and markets nutritional products and devices for customers big and small. A long-held division of Abbott Laboratories, over the years, it has acquired a portfolio of brands that serve multiple niches of the nutritional supplement market. Its infant items include Isomil, PediaSure, Pedialyte, and Similac. In addition, Abbott Nutrition makes adult and diabetic products under brand names such as Ensure, Glucerna, ProSure, and TwoCal. The company also boasts a lengthy list of enteral (feeding) products.

BioMS Medical Corp. was founded in 1998 and is headquartered in Edmonton, Canada. BioMS Medical Corp., a development stage biotechnology company, through its subsidiaries, engages in the development and commercialization of therapeutic technologies for the treatment of multiple sclerosis (MS) in Canada. Its lead product under development includes Dirucotide for the treatment of multiple sclerosis, which is being evaluated in two pivotal Phase III clinical trials for secondary progressive MS patients; and MAESTRO-01, a pivotal phase II/III trial in Canada and western Europe. The company also develops Maestro-02, an open-label follow-on study to the Maestro-01 pivotal phase II/III clinical trial of Dirucotide, which targets secondary progressive multiple sclerosis (SPMS), as well as MAESTRO-03 trial, a pivotal Phase III product to evaluate the safety and efficacy of Dirucotide in patients with SPMS in the United States. BioMS Medical Corp. has a licensing and development agreement with Eli Lilly and Company. The company was formerly known as EPS Capital Corp. and changed its name to BioMS Medical Corp. in July 2001.

Metabasis Therapeutics, Inc. company was founded in 1997 and is based in La Jolla, California. Metabasis Therapeutics, Inc. (Metabasis) is a biopharmaceutical company focused on the discovery development of drugs. The Company’s product pipeline includes product candidates and advanced discovery programs for the treatment of metabolic diseases such as diabetes and hyperlipidemia, which it refer to as its core assets, as well as product candidates and advanced discovery programs for the treatment of liver diseases such as hepatitis and primary liver cancer, which it refer to as its non-core assets. All of its product candidates were developed internally using its HepDirect technology. The Company’s pipeline of clinical-stage product candidates also consists of its core asset, MB07803, a product candidate for the treatment of type 2 diabetes, and its non-core assets, pradefovir and MB07133, developed for the treatment of hepatitis B and primary liver cancer, respectively.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.